DelfaGLP-1 Atlas

Lead sponsor

Boehringer Ingelheim

36 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

36

Trials led

9

Active

298,824

Total enrollment

1,436

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
20
Phase 2
3
Phase 3
8
Phase 4
1
Not applicable
4

Trials by status

Recruiting
4
Active, not recruiting
5
Completed
27

Trials led

Comparative Effectiveness of Empagliflozin in the US—not applicableActive, not recruiting230,000
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes—not applicableCompleted26,774
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists—not applicableCompleted24,500
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)BMI ≥27 · Established CVDPh 3Active, not recruiting5,531
DIA_CENTRAL:T2D Treatment Pattern in Central Europe—not applicableCompleted4,083
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis—Ph 3Recruiting1,800
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisBMI ≥27Ph 3Recruiting1,590
SYNCHRONIZE™-2BMI ≥27Ph 3Completed755
SYNCHRONIZE™-1BMI ≥30Ph 3Completed726
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.BMI 25-50Ph 2Completed413
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightBMI ≥27Ph 2Completed387
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightBMI ≥28Ph 3Completed307
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)—Ph 2Completed295
SYNCHRONIZE™JPHbA1c ≥6.5%Ph 3Completed274
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)BMI ≥30Ph 3Completed218
A Study to Test Different Doses of BI 456906 in Patients With ObesityBMI 27-40Ph 1Completed131
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityBMI 27-39.9Ph 1Completed110
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyBMI 27-39.9Ph 1Active, not recruiting100
A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With LiraglutideBMI 25-34.9Ph 1Completed95
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906BMI 27-40Ph 1Completed88
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906BMI 18.5-40Ph 1Completed82
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyBMI 27-39.9Ph 1Recruiting80
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RABMI ≤40Ph 4Completed65
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityBMI 30-45Ph 1Active, not recruiting64
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorBMI 22-39.9Ph 1Active, not recruiting56
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsBMI 20-40Ph 1Completed42
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2BMI 23-40Ph 1Completed37
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityBMI 27-39.9Ph 1Completed34
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodBMI 27-40Ph 1Completed32
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverBMI 30-40Ph 1Recruiting30
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyBMI ≥30Ph 1Completed30
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyBMI 20-29.9Ph 1Completed30
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityBMI 27-40Ph 1Completed23
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersBMI 20-29.9Ph 1Completed20
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyBMI 18.5-29.9Ph 1Completed16
A Study in Healthy Men to Test How BI 456906 is Processed in the BodyMale · Healthy volunteersPh 1Completed6